TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3165
Abstract: Purpose: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion–positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic… read more here.
Keywords: trk inhibitors; trk fusions; trk fusion; trk ... See more keywords
Larotrectinib OK'd for Cancers with TRK Fusions.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-163
Abstract: Larotrectinib, a first-in-class TRK inhibitor, received accelerated approval for patients of all ages with solid tumors harboring NTRK fusions. It's the first tissue-agnostic marketing authorization for a targeted therapy and the first time a drug's… read more here.
Keywords: cancers trk; larotrectinib cancers; trk fusions;